Fox Chase Cancer Center News

PHILADELPHIA (October 31, 2022)—Robert Uzzo, MD, MBA, FACS, has been formally named President and CEO of Fox Chase Cancer Center following a period of interim leadership.

PHILADELPHIA (October 25, 2022)—A small subset of patients who undergo treatment for head and neck cancer may require a gastrostomy tube many years into survivorship, according to a study presented today by researchers from Fox Chase Cancer Center at the annual meeting of the American Society for Radiation Oncology.

PHILADELPHIA (October 23, 2022)—It’s common for lung cancer patients receiving radiation therapy to miss a few treatment days. But how many missed days is too many? And can providers make up for the delayed treatments by increasing the radiation dose?

PHILADELPHIA (October 21, 2022)—Jessica Karen Wong, MD, MEng, of Fox Chase Cancer Center will discuss new trends in the management of oligometastatic prostate cancer, including the increased use of localized treatments such as radiation that are increasing local control and improving outcomes.

PHILADELPHIA (October 21, 2022)—Shelly Hayes, MD, director of Fox Chase Cancer Center Buckingham and associate professor in the Department of Radiation Oncology, was recently presented with an inaugural Earth Angel Award during the 5th Annual Pine2Pink event in Doylestown.

PHILADELPHIA (October 21, 2022)—Fox Chase Cancer Center’s Andrea Porpiglia, MD, MSc, FACS, assistant professor in the Department of Surgical Oncology, was recently inducted as a fellow into the Philadelphia Academy of Surgery.

PHILADELPHIA (October 20, 2022)—A team of advanced practice providers in the Department of Hematology/Oncology at Fox Chase Cancer Center have received the 2021 Article of the Year Award from the Journal of the Advanced Practitioner in Oncology (JADPRO). This award is given to one article each year that demonstrates an exceptional contribution to the body of literature for oncology advanced practice.

PHILADELPHIA (October 18, 2022)—The development of a family of drugs known as Bruton tyrosine kinase inhibitors (BTKi) was a huge step forward in treating chronic lymphocytic leukemia and non-Hodgkin lymphoma.